Obe-Cel Is Effective in R/R B-ALL Patients with Low CAR-HT Risk

Fact checked by Kyle Doherty
News
Article

Obe-cel shows efficacy in R/R B-ALL, especially in those with a favorable CAR-HT risk profile, according to data from the phase 1/2 FELIX study.

Obe-cel shows efficacy in R/R B-ALL, especially in those with a favorable CAR-HT risk profile, according to data from the phase 1/2 FELIX study.

Obe-cel shows efficacy in R/R B-ALL, especially in those with a favorable CAR-HT risk profile, according to data from the phase 1/2 FELIX study.

Patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) who have low-risk CAR-HEMATOTOX (CAR-HT) scores experienced improved outcomes with obecabtagene autoleucel (obe-cel; Aucatzyl) compared with those who had high-risk scores, according to an analysis of the phase 1/2 FELIX trial (NCT04404660) presented at the 2025 Tandem Meeting.1

Patients treated with obe-cel during the study (n = 127) were divided into subgroups based on low-risk or unknown (n = 25) or high-risk (n = 102) CAR-HT scores. At a median follow-up of 21.5 months (range, 8.6-41.4), patients in the low-risk group experienced an overall response rate (ORR) of 96.0% (95% CI, 79.6%-99.9%) compared with 73.5% (95% CI, 63.9%-81.8%) for those in the high-risk group. Additionally, 20.8% of patients in the low-risk group proceeded to allogeneic stem cell transplant (allo-SCT) vs 17.3% of patients in the high-risk group.

In the low-risk group, the median duration of remission (DOR), event-free survival (EFS), and overall survival (OS) were all not evaluable (NE). In the high-risk group, patients experienced a median DOR of 14.2 months (95% CI, 8.2-NE), a median EFS of 9.0 months (95% CI, 5.8-15.1), and a median OS of 14.1 months (95% CI, 10.7-17.1).

“The CAR-HT risk score correlated with disease burden in this patient population,” lead study author Karamjeet Sandhu, MD, said in a presentation of the data. “Risk stratification for hematotoxicity could provide an early indicator for [the] likelihood of treatment benefit and guiding treatment decisions for some of these subgroups.”

In November 2024, the FDA approved obe-cel for the treatment of adult patients with relapsed or refractory B-cell precursor ALL, based on previously reported data from FELIX.2

Digging into the CAR-HT Analysis Methodology

The CAR-HT model was created to stratify patients with large B-cell lymphoma into groups based on the risk of hematotoxicity prior to the receipt of CAR T-cell therapy.1 FELIX study investigators adapted this model for relapsed/refractory B-ALL with the goal of evaluating its potential role as an early indicator of treatment benefit with obe-cel.

The model accounts for baseline characteristics such as platelet count, absolute neutrophil count, hemoglobin level, c-reactive protein level, and ferritin level; between 0 and 1 points are assigned for each parameter, except for platelet count and ferritin level, where 0 to 2 points could be assigned. Patients with less than 2 total points are considered low-risk; those with 2 or more points are deemed high risk.

FELIX enrolled patients at least 18 years of age with relapsed/refractory B-ALL. The trial included 3 cohorts: cohort A enrolled patients with a bone marrow blast level of at least 5% at screening; cohort B included patients with minimal residual disease (MRD)–positive disease at screening; and cohort C enrolled patients with isolated extramedullary disease at screening.

After leukapheresis, patients were allowed to undergo bridging therapy prior to receiving lymphodepleting chemotherapy with 30 mg/m2 of fludarabine per day for 4 days and 500 mg/m2 of cyclophosphamide per day for 2 days. Obe-cel was administered as a split-dose infusion. Patients with a bone marrow blast level of no more than 20% received the agent at 100 x 106 CAR T cells on day 1, then 310 x 106 CAR T cells on day 10. Those with a bone marrow blast level above 20% received obe-cel at 10 x 106 CAR T cells on day 1 and 400 x 106 CAR T cells on day 10. Irrespective of the split-dosing regimen, the final target dose was 410 x 106 CAR T cells.

The trial’s key end points included complete response (CR)/CR with incomplete hematologic recovery rate; DOR; EFS; OS; MRD-negativity rate; safety; CAR T-cell expansion and persistence; and manufacture feasibility.

The median age was 54.0 years (range, 26-81) in the low-risk group vs 46.5 years (range, 20-77) in the high-risk group. Seventy-two percent of patients in the low-risk group were male compared with 47.1% of patients in the high-risk group. Twenty-eight percent and 30.4% of patients were Hispanic/Latino, respectively.

Patients in the low-risk group received a median of 2 prior lines of therapy (range, 1-5) vs 2 prior lines (range, 1-6) in the high-risk group. Forty-eight percent and 32.4% received at least 3 prior lines of therapy, respectively. Eighty percent of patients in the low-risk group received prior treatment with blinatumomab (Blincyto) or inotuxumab ozogamicin (Besponsa) vs 51.0% of patients in the high-risk group. Twenty-four percent and 14.7% of patients, respectively, received both agents. Prior allo-SCT was received by 56.0% of patients in the low-risk group vs 41.2% of patients in the high-risk group.

Sixteen percent and 5.9% of patients in the low- and high-risk groups, respectively, had Philadelphia chromosome (Ph)–like disease; the respective rates of Ph-positive disease were 36.0% and 26.5%. Twenty percent and 21.6% of patients, respectively, had extramedullary disease at lymphodepletion. The median bone marrow blast level at lymphodepletion was 7.0% (range, 0%-90%) in the low-risk group vs 45.5% (range, 0%-100%).

Eighty-four percent of patients in the low-risk group underwent bridging therapy during the study compared with 95.1% of patients in the high-risk group. Bridging therapy for low-risk patients included chemotherapy alone (48.0%), chemotherapy plus a TKI (8.0%), chemotherapy plus inotuxumab ozogamicin (8.0%), inotuxumab ozogamicin alone (4.0%), and a TKI alone (16.0%). In high-risk patients, bridging therapies comprised chemotherapy alone (66.7%), chemotherapy plus a TKI (7.8%), chemotherapy plus inotuxumab ozogamicin (6.9%), inotuxumab ozogamicin alone (7.8%), a TKI alone (2.9%), steroids (2.0%), and other (1.0%).

CAR-HT scores were correlated with disease burden at lymphodepletion. In the low-risk group, 60.0% of patients had a bone marrow blast level of no more than 20% compared with 36.3% of patients in the high-risk group. A bone marrow blast level of more than 75% was observed in 8.0% of patients in the low-risk group vs 37.3% of patients in the high-risk group.

Safety by CAR-HT Risk Group

The rates of any-grade cytokine release syndrome (CRS) were 56.0% in the low-risk group vs 71.6% in the high-risk group. The respective rates of grade 3 or higher CRS were 0% and 2.9%. The median time to onset of CRS was 10.0 days (range, 2.0-14.0) and 8.0 days (range, 1.0-23.0), respectively, and the respective durations of CRS were 4.0 days (range, 1.0-6.0) and 6.0 days (range, 1.0-21.0).

Any-grade immune effector cell–associated neurotoxicity syndrome (ICANS) occurred in 12.0% of patients in the low-risk group vs 25.5% of patients in the high-risk group. The rates of grade 3 or higher ICANS were 8.0% and 6.9%, respectively. The respective times to onset of ICANS were 11.0 days (range, 3.0-15.0) and 12.5 days (range, 1.0-31.0). The duration of ICANS was 8.0 days (range, 5.0-8.0) in the low-risk group vs 8.5 days (range, 1.0-53.0) in the high-risk group.

Any-grade infections were reported in 50.0% of patients in the low-risk group vs 57.3% of patients in the high-risk group. The rates of grade 3 or higher infections were 12.5% and 26.7%, respectively.

Deaths at any time following obe-cel infusion occurred in 24.0% of patients in the low-risk group vs 56.9% of patients in the high-risk group.

The median time to neutrophil count recovery was 0.8 months (95% CI, 0.7-1.9) in the low-risk group vs 1.9 months (95% CI, 1.5-2.0) in the high-risk group. The respective times to platelet count recovery were 0.6 months (95% CI, 0.0-1.9) and 2.1 months (95% CI, 1.9-2.3).

A Look at the ALL-Hematotox Model

Since the majority of patients enrolled in FELIX were classified as high risk using the CAR-HEMATOTOX model, investigators also explored the ALL-Hematotox (ALL-HT) model released by the National Cancer Institute in 2024. The 2 models use similar parameters, except ALL-HT replaces ferritin levels with bone marrow blast percentage. Additionally, 3 total points or fewer is considered low risk in this model.

When reclassifying patients based on the ALL-HT model, 43.3% of patients (n = 55) fell into the low-risk/unknown group, and 56.7% (n = 72) were considered high risk.

Using the ALL-HT model, the median DOR and EFS were both NE for the low-risk group. For the high-risk group, the median DOR was 11.0 months (95% CI, 5.2-21.2), and the median EFS was 5.7 months (95% CI, 2.8-9.0).

“A preliminary analysis using the ALL-HT model identified a greater proportion of patients [as] low risk [compared with] the CAR-HT model. We look forward to presenting a full analysis [using the ALL-HT model] at a future congress,” Sandhu concluded.

Disclosures: Dr Sandhu reported serving as a consultant for Autolus Therapeutics.

References

  1. Sandhu KS, Park JH, Shaughnessy P, et al. Risk factors associated with sub-optimal outcomes and hematotoxicity following obecabtagene autoleucel (obe-cel) for relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL). Presented at: 2025 Transplant and Cellular Therapy Meetings; February 12-15, 2025; Honolulu, HI. Abstract 10.
  2. FDA approves obecabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. FDA. November 8, 2024. Accessed February 13, 2025. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-obecabtagene-autoleucel-adults-relapsed-or-refractory-b-cell-precursor-acute
Recent Videos
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight the many advantages to attending the 42nd Annual Miami Breast Cancer Conference, with some additional tidbits to round out the main event.
Both clinicians and patients should have as much information as possible to participate in shared decision-making for CLL care, says Jacob D. Soumerai, MD.
Sequencing different treatments in the first 3 lines of therapy represents a challenge in chronic lymphocytic leukemia, according to Deborah Stephens, DO.
Other ongoing urothelial cancer trials are assessing enfortumab vedotin–based combinations in the neoadjuvant setting.
Given resource scarcity, developing practice strategies for resource-constrained settings would require aid from commercial and government stakeholders.
Approximately 95% of those with a complete response to enfortumab vedotin plus pembrolizumab were alive after 2 years in the phase 3 EV-302 trial.
Related Content